# A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

> **NCT03570931** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biojiva LLC** · enrollment: 19 (actual)

## Conditions studied

- Infantile Neuroaxonal Dystrophy

## Interventions

- **DRUG:** RT001

## Key facts

- **NCT ID:** NCT03570931
- **Lead sponsor:** Biojiva LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-05
- **Primary completion:** 2020-08-09
- **Final completion:** 2022-06-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03570931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03570931, "A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03570931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*